Companies in #Solid Tumor Oncology
Found 2 companies operating in this sector.
Elicio Therapeutics is a clinical-stage biotechnology company developing potent immunotherapies using its proprietary Amphiphile vaccine platform, which delivers immunogens directly to the lymph nodes to amplify immune responses against cancer. Its lead program ELI-002 is a KRAS-targeted cancer vaccine being studied in mKRAS-positive pancreatic ductal adenocarcinoma and other solid tumors. In June 2026 the Phase 2 AMPLIFY-201 trial missed its primary endpoint, sending shares down sharply, though the company said it will still advance to a Phase 3 study based on a subpopulation signal.
Ernexa Therapeutics is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing engineered mRNA cell therapies for advanced cancer and autoimmune disease. The company's pipeline is built on a patented mRNA cell-engineering platform designed to program immune cells in vivo, with a focus on solid-tumor and immune-mediated indications. Ernexa trades on Nasdaq under the symbol ERNA and executed a 1-for-25 reverse stock split effective May 4, 2026 to address its minimum-bid-price listing compliance. In July 2026 the company furnished an updated investor presentation via Form 8-K, refreshing materials originally posted in February 2026 to provide current company information and forward-looking statements to investors.